论文部分内容阅读
类风湿关节类(rheumatoid arthritis,RA)是一种以关节滑膜慢性炎症病变为主要特征的自身免疫性疾病。我国的患病率为0.32%~0.36%,是造成我国人群丧失劳动力和致残的主要病变之一[1]。目前治疗RA的主要方法是根据病情选取非甾体类抗炎药(NSAIDs)、抗风湿药(DMARDs)、甾体类药物以及分子靶标药物(生物制剂)等,单独或联合应用。但这些化学药物及生物制剂在有效快速控制症状、缓解改善病情上仍存在一定的局限性,如治疗过程中多药耐药的产生严重
Rheumatoid arthritis (RA) is an autoimmune disease characterized mainly by chronic inflammatory synovial lesions. The prevalence in our country is 0.32% ~ 0.36%, which is one of the major diseases that cause the loss of labor force and disability in our country [1]. The current treatment of RA is based on the disease selection of non-steroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs (DMARDs), steroidal drugs and molecular target drugs (biological agents), etc., alone or in combination. However, these chemical drugs and biological agents in the effective and rapid control of symptoms, to alleviate the improvement of the disease there are still some limitations, such as the course of treatment of multi-drug resistance serious